Honoring U.S. Senator Jon Kyl
As Arizona celebrated its Centennial, AZBio honored Arizona Senator Jon Kyl for his dedication and service to both our industry and the people of our state with the 2012 AZBio Centennial Award. Senator Kyl is serving his third and final term in the U.S. Senate after previously serving for eight years in the U.S. House of Representatives. He was elected unanimously by his colleagues in 2008 to serve as Republican Whip, the second-highest position in Senate Republican leadership. Enjoy Senator Kyl's remarks about Arizona's Bioindustry and the introduction by Fritz Bittenbender of the Biotechnology Industry Association (BIO)
Linda Hunt of Dignity Health Arizona, 2013 Arizona Bioscience Leader of the Year
The Jon W. McGarity Arizona Bioscience Leader of the Year Award honors the person in Arizona who provided the most outstanding leadership that contributed significantly to development of the State’s bioindustry and/or recognition of the advancement of bioscience in Arizona. Recognizing that collaboration builds a stronger community, Linda Hunt has taken a leadership role to advance healthcare and the biosciences for the people of Arizona. Hunt has worked diligently with legislators, business leaders, educators, scientists and community organizations in order to identify, formulate, and support policies that will give Arizonans better healthcare and raise the bar of knowledge.Hunt has served as the head of Dignity Health in Arizona since 2012. Dignity Health includes three major hospitals in the Valley, St. Joseph’s Hospital and Medical Center and Chandler Regional and Mercy Gilbert Medical Centers. A fourth hospital, St. Joseph’s Westgate, is under construction.
Amanda Grimes 2013 Arizona Bioscience Educator of the Year
Some of the most important messages AZBio received about Mrs. Grimes work came from students she has helped to inspire: “She has taught each and every one of us that science can be fun too. A lot of people get stuck on the math but she opens it up to where it’s interesting and reels you in like a fish on a hook.” “As a high school graduate I can look back upon my time as a student and pick out a few teachers who have influenced my life and helped me flourish as a student. The number one teacher on that list is Mrs. Grimes. Having had Mrs. Grimes as a teacher for two years has helped me make connections, plan my future, and given me opportunities no other teachers have ever attempted. Without Mrs. Grimes I never would have joined the Biotech Academy at Mesa High School, meaning I would never have discovered my love for science and research.” “One of Mrs. Grimes’ most admirable qualities would be her patience with her students. Mrs. Grimes’ never ending patience and abundant respect for her students makes her an extraordinary teacher and mentor, always willing to answer questions or stay late to help. She does everything she can to ensure her students have every opportunity to advance their knowledge and experience beyond that of a typical high school student.” “Mrs. Grimes always encourages her students to excel in every aspect of their life, whether that be academics, community service, or extracurricular activities. I, and many of my peers, admire Mrs. Grimes for her dedication to her career and her students and wouldn’t be where we are if it weren't for her model of excellence.” “She has opened my eyes to the world of biotechnology and I am enthralled to be a part of it, I will not go quietly in this field.” The Biotechnology Academy (Mesa Public Schools) is a four-year program that provides freshmen-senior high students with experience in biotechnology theory and techniques, and prepares them for continuing education in Biotechnology Degree programs or related fields.
A Global Perspective from executives of Arizona’s Bioscience Companies on why they are in Arizona Panelists Bob Bosserman, CEO, Medelis Janet Spear, Plant Manager, Celgene Joan Koerber-Walker, president & CEO, AZBio (moderator) Dr. Ken Wertman, Scientific Director, Sanofi, Oro Valley Dr. Phil Miller, Ventana Filmed live at the 2011 AZBio Expo
Raymond L. Woosley, MD, PhD - 2012 AZBio Pioneer
Raymond L. Woosley earned a Ph.D. in Pharmacology from the University of Louisville and an M.D. from the University of Miami. He began his career as the first scientist in the US operations for Glaxo, now known as GlaxoSmithKline. Dr. Woosley specialized in Internal Medicine and Clinical Pharmacology at Vanderbilt University where he rose to the rank of Professor of Medicine. At Georgetown University he served as Chairman of the Department of Pharmacology and in 2000 was appointed Associate Dean for Clinical Research. In 2001 he became Vice President for Health Sciences at the University of Arizona and Dean of the College of Medicine. In January of 2005 he assumed the position of President of The Critical Path Institute (C-Path), a non-profit corporation formed by the Food and Drug Administration, SRI, International and the University of Arizona to accelerate the development of safe innovative medicines. Since 1999, he has directed one of seven federally-funded (Agency for Healthcare Research and Quality) Centers for Education and Research on Therapeutics (CERT).Under Dr. Woosley’s leadership, C-Path (the Critical Path Institute) orchestrated the acceleration of medical product development through a unique collaborative process among industry, academia, and the FDA. Our collaborations among 6 global consortia, 1000+scientists, and 41 companies has already produced these notable successes: First preclinical safety biomarkers (7) qualified by the FDA, EMA, and PMDA (the Japanese counterpart) First CDISC (Clinical Data Interchange Standards Consortium) therapeutic area data standard First and largest open database of CDISC aggregated clinical trial data for Alzheimer’s disease (6,100 patients and 22 clinical trials) Read more First drug-disease trial model & clinical trial simulation tool submitted and under review by the FDA First imaging biomarker for trial enrichment qualified by the EMA Dr. Woosley’s research has investigated the basic and clinical pharmacology of drugs for the treatment of arrhythmias and the cardiac toxicity of drugs, and has been published in over 260 publications. His research discovered the mechanism of the toxicity of the antihistamine Seldane®. He is the recipient of the Rawls-Palmer Award from the American Society of Clinical Pharmacology and Therapeutics for his contributions to medicine and the FDA Commissioner’s Special Citation for his work to advise the agency on the toxicity of dietary supplements containing ephedra. Dr. Woosley is a Past-President of the Association for Medical School Pharmacology and the American Society for Clinical Pharmacology and Therapeutics. He has served on numerous boards including the US Pharmacopeia. He is a member of the Biodesign Institute at Arizona State University. As a member of the University of Arizona’s Sarver Heart Center and Bio5 Institute, he conducts research on the prevention of adverse drug interactions.
AZBio Expo 2011 Company Spotlight
The 2011 AZBio Expo brought together innovative and life saving companies from across the state along with leaders from across the industry. Be sure to check out the highlights and a special spotlight interview where Don Isaacs, VP of Communications at SynCardia Systems, Inc. brings EmpowHER's Shana O'Conner up close and personal with the world's only Total Artificial Heart. It's why SynCardia was named the 2011 Bioscience Company of the Year.
2012 State of the Industry: John D. Carroll of FierceBiotech
John D. Carroll is a biotech analyst with 34 years of prize-winning experience in journalism. Appointed editor of FierceBiotech in 2003, he has covered virtually every aspect of the global drug development industry over the past decade. His work includes the popular Fierce 15, which recognizes the most innovative private companies in the business each year. His daily reports keep more than 100,000 subscribers around the world clued in to the latest developments on deals, data and industry trends. Carroll plans to address the biggest influences affecting the fast-changing biopharma industry and what it means to biotech executives in Arizona.